PubMed

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE.

Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.PMID: 17909087 [PubMed - indexed for MEDLINE]Related articlesFree article

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE.

J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. Epub 2007 Nov 27.PMID: 18042650 [PubMed - indexed for MEDLINE]Related articlesFree article

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE.

J Clin Endocrinol Metab. 2009 Apr;94(4):1236-43. Epub 2009 Jan 27.PMID: 19174497 [PubMed - indexed for MEDLINE]Related articles

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA.

J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. Epub 2007 Aug 14.PMID: 17698900 [PubMed - indexed for MEDLINE]Related articlesFree article

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR.

Diabetologia. 2006 Sep;49(9):2049-57. Epub 2006 Jul 1.PMID: 16816950 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE.

Diabetes Obes Metab. 2008 Aug;10(8):675-82. Epub 2007 Nov 22.PMID: 18248490 [PubMed - indexed for MEDLINE]Related articles

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE.

Diabetes Obes Metab. 2008 Nov;10(11):1114-24. Epub 2008 Mar 18.PMID: 18355325 [PubMed - indexed for MEDLINE]Related articles

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.

J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. Epub 2008 Oct 28.PMID: 18957505 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M.

Clin Pharmacokinet. 2007;46(7):577-88.PMID: 17596103 [PubMed - indexed for MEDLINE]Related articles

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA.

J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23.PMID: 17244786 [PubMed - indexed for MEDLINE]Related articlesFree article

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.

Ahrén B, Foley JE.

Int J Clin Pract Suppl. 2008 Mar;(159):8-14. Review.PMID: 18269436 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE.

J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94. Epub 2005 May 10.PMID: 15886245 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE.

J Clin Endocrinol Metab. 2008 Jan;93(1):103-9. Epub 2007 Oct 9.PMID: 17925336 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

Ahrén B, Pacini G, Foley JE, Schweizer A.

Diabetes Care. 2005 Aug;28(8):1936-40.PMID: 16043735 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.

Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.

Horm Metab Res. 2007 Nov;39(11):826-9.PMID: 17992639 [PubMed - indexed for MEDLINE]Related articles

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.

Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S.

Diabetes Obes Metab. 2008 Sep;10(10):931-8. Epub 2007 Dec 17.PMID: 18093207 [PubMed - indexed for MEDLINE]Related articles

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M.

Clin Endocrinol (Oxf). 2008 Nov;69(5):737-44. Epub 2008 Mar 10.PMID: 18331607 [PubMed - indexed for MEDLINE]Related articles